Nurix Therapeutics IncNRIX
Price$23.34Intrinsic value$10.6554% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $36.8M-32.6% YoYTTM through 31 May 2026
Net Income -$341.4MTTM through 31 May 2026
Free Cash Flow -$304.5MTTM through 31 May 2026

Margins

Current
EBITDA Margin-959.0%
Operating Margin-1,466.7%
Net Margin-928.4%

Returns

-61.4%ROE
-46.4%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio6.34x
Net Debt-$540.7Mnet cash position
Cash & Equivalents$67.7M

Quality Metrics

Altman Z-Score7.65
Piotroski F-Score2 / 9
FCF Margin-828.3%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $84M
Diluted EPS-$3.46TTM
'21'22'23'24'25
FY2025: $-3.05

Dividend

No dividend

Capital Allocation

Capex Intensity29.4%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.